Immunogenicity and safety of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults ≥18 years of age in India: A phase 3 single-arm trial.
Balachandra Giriappa, Nirmalkumar Choraria, Philip Ponce et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 3, multicenter, single-arm trial assessed immunogenicity and safety of one dose of 20-valent pneumococcal conjugate vaccine (PCV20) in pneumococcal vaccine-naive adults aged ≥18 years in India. All 400 participants, split equally between ages 18–49 and ≥50 years, were vaccinated. At 1 month, opsonophagocytic activity geometric mean titers increased for all 20 serotypes; geometric mean fold rises ranged from 5.9 to 49.8 for PCV13 serotypes and 5.4 to 75.7 for the seven additional PCV20 serotypes. The vaccine was generally well tolerated, with no related or serious adverse events reported.
Key findings
- OPA geometric mean titers increased from baseline for all 20 serotypes at 1 month after vaccination.
- GMFRs ranged from 5.9 (serotype 14) to 49.8 (23F) for PCV13 serotypes and from 5.4 (11A) to 75.7 (12F) for the seven additional serotypes.
- Any adverse event through 1 month was reported by 2.3% of participants; no related, immediate, severe, or serious adverse events were reported.
- Most local reactions and systemic events were mild or moderate and transient.
Why it matters
The findings provide India-specific evidence that a single PCV20 dose can elicit immune responses across all 20 included serotypes in adults aged 18 years and older, while showing an acceptable short-term safety profile in this study. This is relevant where expanded-valent pneumococcal vaccination for older adults is an identified unmet need, although the trial does not establish clinical protection against pneumococcal disease.
What to keep in mind
The single-arm design had no comparator, and immunogenicity was assessed at 1 month; the abstract does not report clinical disease outcomes or longer-term protection.